Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1 9Phase 3 2Phase 1/2 2Phase NA 1Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Ovarian Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 6Breast Neoplasms 6Metastatic Castration-resistant Prostate Cancer 3Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Hematologic Neoplasms 1HER2-ve Metastatic Breast Cancer 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 23Carboplatin 22Capecitabine 18Gemcitabine 16130-nm albumin-bound paclitaxel 16pembrolizumab 14Cyclophosphamide 12atezolizumab 9Epirubicin 9sacituzumab govitecan 8Albumin-Bound Paclitaxel 8eribulin 6Vinorelbine 6Drug Therapy 6Doxorubicin 6camrelizumab 4Docetaxel 4Cisplatin 4Injections 3pegfilgrastim 2olaparib 2famitinib 2Filgrastim 2Everolimus 2veliparib 1trilaciclib 1toripalimab 1taxane 1niraparib 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Triple Negative Breast Neoplasms × olaparib × Clear all
NCT06966700 2026-06-01

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Merck Sharp & Dohme LLC

Phase 3 Recruiting
2,400 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07486687 2026-03-20

PLANET

The Netherlands Cancer Institute

Phase 3 Not yet recruiting
1,000 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡